Calidi Biotherapeutics Inc
calidibio.comWhat Do They Do?
Develops engineered viruses that deliver genetic medicines to tumors for people with cancer.
10-K for FY2025, filed Mar 27, 2026We are a publicly traded biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic…View ↗
More recently, we used the learnings from NeuroNova and SuperNova to create RedTail, a novel oncolytic viral platform that avoids immune…View ↗
The RedTail platform utilizes an engineered vaccinia virus enveloped by a cell membrane and engineered to express CD55. In syngeneic animal…View ↗
How Do They Make Money?
$45K
-
10-K for FY2023, filed Mar 15, 2024
$45K ↗
Do Revenues Turn Into Profits?
No. It lost $25.4M in FY2022.
10-K for FY2023, filed Mar 15, 2024
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$4.2MView ↗
- ▼ −27% (Loss)
- vs −$5.7M in Q2 FY2025
From merger search to drug development
Changed from a shell company formed to find a business combination into a biotechnology company developing engineered viruses that deliver genetic medicines to tumors.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 27, 2026We are a blank check company formed on March 24, 2021 as a Delaware corporation whose business purpose is to effect a merger, capital stock…View ↗
We are a publicly traded biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic…View ↗
Who Do They Compete With?
Competes with AstraZeneca, Bristol-Myers Squibb, Gilead Sciences, Merck &, Novartis, Pfizer, Genentech, Oncorus, Replimune Group, Amgen, ImmVira, IconOVir Bio, Candel Therapeutics, CG Oncology, Genelux, Imugene, Viromissile, Oncolytics Biotech, and FerGene
10-K for FY2025, filed Mar 27, 2026The development and commercialization of new product candidates is highly competitive. We face competition from major pharmaceutical…View ↗
Loading...
